| Literature DB >> 34234537 |
Gaoliang Yan1, Dong Wang1, Chengchun Tang1, Genshan Ma1.
Abstract
OBJECTIVE: The association of lactate and contrast-induced acute kidney injury (CI-AKI) has not been well established. This prospective study was planned to identify the effects of lactate level on the occurrence of CI-AKI and long-term prognosis with acute myocardial infarction (AMI) patients undergoing emergency percutaneous coronary intervention (PCI).Entities:
Keywords: acute kidney injury; contrast media; lactate; myocardial infarction; percutaneous coronary intervention; prognosis
Year: 2021 PMID: 34234537 PMCID: PMC8257073 DOI: 10.2147/IJGM.S316036
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Figure 1Study flow chart.
Baseline Clinical Characteristics Between Patients with CI-AKI and Those without CI-AKI
| Variables | All Patients (n=280) | CI-AKI (n=64) | Non-CI-AKI (n=216) | |
|---|---|---|---|---|
| Age (years) | 63±13 | 66±14 | 61±13 | 0.014 |
| Male, n (%) | 218(77.9) | 46(71.9) | 172(79.6) | 0.230 |
| BMI (kg/m2) | 24.1±2.9 | 25.0±2.9 | 23.8±2.9 | 0.008 |
| Systolic BP (mmHg) | 128±22 | 125±23.0 | 129±21.2 | 0.136 |
| Diastolic BP (mmHg) | 77±14 | 74.1±14.3 | 77.6±13.4 | 0.077 |
| HR (times/min) | 81±16 | 82.5±14.7 | 80.1±16.1 | 0.289 |
| Smoking, n (%) | 125(44.6) | 38(59.4) | 87(40.3) | 0.010 |
| Hypertension, n (%) | 179(63.9) | 39(60.9) | 140(64.85) | 0.657 |
| Diabetes mellitus, n (%) | 85(30.4) | 17(26.6) | 68(31.5) | 0.537 |
| OMI, n (%) | 15(5.4) | 5(7.8) | 10(4.6) | 0.345 |
| Pre-PCI, n (%) | 27(9.6) | 11(17.2) | 16(7.4) | 0.029 |
| Stroke, n (%) | 13(4.6) | 5(7.8) | 8(3.7) | 0.182 |
| LVEF, (%) | 43(39,46) | 41(37,45) | 43(40,47) | 0.003 |
| STEMI, n (%) | 126(45.0) | 26(40.6) | 100(46.3) | 0.476 |
| Lactate (mmol/L) | 2.6(2.0,3.1) | 3.3(2.6,4.5) | 2.5(1.9,2.9) | <0.001 |
| WBC (×109/L) | 10.3(8.0,12.6) | 9.1(7.3,12.0) | 10.6(8.4,12.7) | 0.114 |
| Hemoglobin (g/L) | 140±19 | 135±20 | 141±18 | 0.024 |
| Albumin (g/L) | 37.5±4.8 | 35.5±5.0 | 38.1±4.6 | <0.001 |
| AST (U/L) | 41(28,65) | 47(29,72) | 40(26,65) | 0.290 |
| Pre-creatinine(μmol/L) | 85.2±29.7 | 96.8±35.7 | 75.3±27.6 | 0.013 |
| eGFR | 66.6±14.3 | 53.4±12.6 | 68.4±14.6 | <0.001 |
| TC (mmol/L) | 4.6±1.1 | 4.6±1.2 | 4.7±1.1 | 0.586 |
| LDL-C (mmol/L) | 2.9±0.8 | 2.9±0.9 | 2.9±0.8 | 0.895 |
| Medications, n (%) | ||||
| IIb/IIIa inhibitors | 224(80.0) | 47(73.4) | 177(81.9) | 0.155 |
| β-blocker | 204(72.9) | 51(79.7) | 153(70.8) | 0.201 |
| ACEI/ ARBs | 168(60.0) | 37(57.8) | 131(60.6) | 0.772 |
| CCB | 36(12.9) | 7(10.9) | 29(13.4) | 0.676 |
| Statins | 255(91.1) | 55(85.9) | 200(92.6) | 0.132 |
| Diuretics | 77(27.5) | 21(32.8) | 56(25.9) | 0.339 |
| Contrast dose, mL | 100(100, 120) | 100(100, 120) | 100(100, 120) | 0.217 |
| Culprit vessel, n (%) | 0.003 | |||
| LAD | 101(36.1) | 31(48.4) | 70(32.4) | |
| LCX | 58(20.7) | 4(6.3) | 54(25.0) | |
| RCA | 121(43.2) | 29(45.3) | 92(42.6) | |
| IABP, n (%) | 28(10.0) | 12(18.8) | 16(7.4) | 0.015 |
| Number of stents, n | 1.9±1.1 | 2.0±1.1 | 1.9±1.1 | 0.361 |
| Hospitalization(days) | 7(5,10) | 9(6–13) | 7(5–9) | 0.001 |
| Hospitalization costs (¥) | 52,416(42,418,69,892) | 61,690(42,705,86,362) | 50,865(42,435,62,044) | 0.012 |
Notes: Data are presented as n (%), mean and standard deviation or median (25th–75th).
Abbreviations: BMI, body mass index; BP, blood pressure; HR, heart rate; OMI, old myocardial infarction; Pre-PCI, pre-percutaneous coronary intervention; LVEF, left ventricular ejection fraction; STEMI, ST-elevation myocardial infarction; WBC, white blood count; AST, glutamic-oxaloacetic transaminase; eGFR, estimated glomerular filtration rate; TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; IABP, intra-aortic balloon pump.
Univariate and Multivariate Logistic Regression Analysis of CI-AKI Risk Factors
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 1.028 | 1.005–1.050 | 0.015 | 0.999 | 0.962–1.038 | 0.978 |
| BMI | 1.146 | 1.035–1.269 | 0.009 | 1.104 | 0.955–1.275 | 0.180 |
| Smoking | 2.167 | 1.228–3.825 | 0.008 | 1.379 | 0.595–3.195 | 0.453 |
| Pre-PCI | 2.594 | 1.137–5.921 | 0.024 | 2.372 | 0.634–8.870 | 0.199 |
| LVEF | 0.910 | 0.864–0.958 | <0.001 | 0.911 | 0.850–0.976 | 0.008 |
| Lactate | 3.558 | 2.348–5.391 | <0.001 | 3.657 | 2.237–5.978 | <0.001 |
| Hemoglobin | 0.983 | 0.968–0.998 | 0.025 | 0.995 | 0.972–1.019 | 0.688 |
| Albumin | 0.891 | 0.837–0.948 | <0.001 | 0.847 | 0.770–0.933 | 0.001 |
| eGFR | 0.361 | 0.193–0.574 | <0.001 | 0.268 | 0.164–0.544 | 0.008 |
| LAD | 1.959 | 1.111–3.454 | 0.020 | 1.254 | 0.576–2.733 | 0.568 |
| IABP | 2.885 | 1.285–6.473 | 0.010 | 3.685 | 1.014–13.389 | 0.048 |
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; DBP, diastolic blood pressure; Pre-PCI, previous percutaneous coronary intervention; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; LAD, left anterior descending; IABP, intra-aortic balloon pump.
Figure 2On receiver operating characteristic curve analysis, the lactate level was an accurate predictor for the development of CI-AKI; the area under the curve was 0.786 for the baseline lactate level (95% CI: 0.712–0.860, p<0.001). The optimum cut-off point of MPO was 3.02mmol/L, with sensitivity of 65.6% and specificity of 85.2%.
Figure 3The correlation between lactate and eGFR (A), and the occurrence of CI-AKI among 2 groups (B).
The 1-Year Follow-Up Clinical Outcomes
| Variables | All Patients (n=280) | High Lactate (n=160) | Control (n=120) | |
|---|---|---|---|---|
| Primary endpoints | 61(21.8%) | 42(26.3%) | 19(15.8%) | 0.035 |
| MACE | 38(13.6%) | 24(15.0%) | 14(11.7%) | 0.402 |
| All-cause death | 7(2.5%) | 5(3.1%) | 2(1.7%) | 0.439 |
| Non-fatal myocardial infarction | 15(5.4%) | 8(5.0%) | 7(5.8%) | 0.785 |
| Target vascular revascularization | 25(8.9%) | 15(9.4%) | 10(8.3%) | 0.727 |
| Re-hospitalization due to heart failure | 17(6.1%) | 14(8.7%) | 3(2.5%) | 0.031 |
| Worsening renal function | 31(11.1%) | 23(14.4%) | 8(6.7%) | 0.038 |
Abbreviation: MACE, major adverse cardiovascular events.
Figure 4The Kaplan–Meier analysis curve of clinical outcomes after 1-year follow-up among 2 groups.
Univariate and Multivariate Cox Regression Analysis for Predictors of Primary Endpoints
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| CI-AKI | 2.141 | 1.269–3.612 | 0.004 | 2.075 | 1.180–3.649 | 0.011 |
| Lactate, ≥3.02mmol/L | 1.775 | 1.032–3.052 | 0.008 | 1.916 | 1.118–3.285 | 0.018 |
| Age, ≥60 y | 2.144 | 1.211–3.793 | 0.009 | 2.537 | 1.332–4.833 | 0.005 |
| STEMI | 0.619 | 0.373–1.026 | 0.063 | 0.584 | 0.339–1.007 | 0.053 |
| Male | 0.687 | 0.392–1.202 | 0.188 | |||
| Smoking | 1.560 | 0.943–2.582 | 0.083 | |||
| Hypertension | 0.845 | 0.506–1.413 | 0.522 | |||
| Diabetes mellitus | 0.968 | 0.558–1.678 | 0.907 | |||
| OMI | 0.584 | 0.143–2.390 | 0.454 | |||
| Pre-PCI | 1.739 | 0.857–3.529 | 0.126 | |||
| Stroke | 1.062 | 0.333–3.391 | 0.919 | |||
| LVEF, <40% | 1.458 | 0.853–2.491 | 0.168 | |||
| LAD-culprit | 1.338 | 0.805–2.222 | 0.261 | |||
| Stents, >1 | 1.305 | 0.774–2.201 | 0.318 | |||
| Albumin, <40g/L | 2.079 | 1.103–3.920 | 0.024 | |||
| eGFR, <90mL/min | 1.858 | 1.107–3.118 | 0.019 | |||
| IABP | 0.803 | 0.322–2.006 | 0.639 | |||
Abbreviations: HR, hazard ratio; CI, confidence interval; CI-AKI, contrast-induced acute kidney injury; STEMI, ST-elevation myocardial infarction; OMI, old myocardial infarction; Pre-PCI, previous percutaneous coronary intervention; LVEF, left ventricular ejection fraction; LAD, left anterior descending; eGFR, estimated glomerular filtration rate; IABP, intra-aortic balloon pump.